These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study. Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372 [TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Richardson PG; Siegel D; Baz R; Kelley SL; Munshi NC; Laubach J; Sullivan D; Alsina M; Schlossman R; Ghobrial IM; Doss D; Loughney N; McBride L; Bilotti E; Anand P; Nardelli L; Wear S; Larkins G; Chen M; Zaki MH; Jacques C; Anderson KC Blood; 2013 Mar; 121(11):1961-7. PubMed ID: 23243282 [TBL] [Abstract][Full Text] [Related]
8. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Leleu X; Attal M; Arnulf B; Moreau P; Traulle C; Marit G; Mathiot C; Petillon MO; Macro M; Roussel M; Pegourie B; Kolb B; Stoppa AM; Hennache B; Bréchignac S; Meuleman N; Thielemans B; Garderet L; Royer B; Hulin C; Benboubker L; Decaux O; Escoffre-Barbe M; Michallet M; Caillot D; Fermand JP; Avet-Loiseau H; Facon T; Blood; 2013 Mar; 121(11):1968-75. PubMed ID: 23319574 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928 [TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone. Li Y; Kassir N; Wang X; Palmisano M; Zhou S J Clin Pharmacol; 2020 Aug; 60(8):1061-1075. PubMed ID: 32168381 [TBL] [Abstract][Full Text] [Related]
12. Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment. Matsue K; Sunami K; Matsumoto M; Kuroda J; Sugiura I; Iwasaki H; Chung W; Kuwayama S; Nishio M; Lee K; Iida S Int J Hematol; 2022 Jul; 116(1):122-130. PubMed ID: 35429329 [TBL] [Abstract][Full Text] [Related]
13. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870 [TBL] [Abstract][Full Text] [Related]
14. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Siegel DS; Schiller GJ; Samaras C; Sebag M; Berdeja J; Ganguly S; Matous J; Song K; Seet CS; Talamo G; Acosta-Rivera M; Bar M; Quick D; Anz B; Fonseca G; Reece D; Pierceall WE; Chung W; Zafar F; Agarwal A; Bahlis NJ Leukemia; 2020 Dec; 34(12):3286-3297. PubMed ID: 32376855 [TBL] [Abstract][Full Text] [Related]
15. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712 [TBL] [Abstract][Full Text] [Related]
16. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma]. Roziaková L; Mistrík M; Bátorová A Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib. Mian M; Pescosta N; Badiali S; Cappelletto PC; Marcheselli L; Luminari S; Patriarca F; Zambello R; Pascarella A; Tagariello G; Marabese A; Mondello P; Billio A; Cortelazzo S Br J Haematol; 2019 Jun; 185(5):944-947. PubMed ID: 30478966 [No Abstract] [Full Text] [Related]
18. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S; Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687 [TBL] [Abstract][Full Text] [Related]
19. Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma. Sheng Z; Liu G Hematol Oncol; 2016 Jun; 34(2):102-7. PubMed ID: 25643940 [TBL] [Abstract][Full Text] [Related]
20. Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). Kalff A; Khong T; Ramachandran M; Ho PJ; Mollee P; D'Rozario J; Taylor K; Estell J; Norton S; Kemp R; Mitchell AJ; Reynolds J; Kennedy N; Quach H; Spencer A Haematologica; 2022 Jan; 107(1):321-325. PubMed ID: 34587718 [No Abstract] [Full Text] [Related] [Next] [New Search]